About US
Contact us
-
J&J notches latest win in long-running talc saga as caseload grows to 5,500As the number of pending talc cases continues to tick upward, Johnson & Johnson is maintaining its defensive winning streak. On Thursday, jurors in Los Angeles sided with the company against a pla2017/11/17
-
Pfizer’s Sutent kidney cancer win should give it a boost, at least until I-O treatments arrivePfizer’s old dog Sutent has shown it has one more trick to perform as a renal cancer treatmentbefore being passed up by the new breed of immuno-oncology drugs. Despite misgivings by an FDA advisory2017/11/17
-
Roche nabs blockbuster FDA approval for Hemlibra, big label expansion for GazyvaCall it a big day for Roche at the FDA, as the drug giant picked up two critical approvals on Thursday, firstfor hemophilia A drug Hemlibra and then with a label expansion for Gazyva. Hemlibrawon2017/11/16
-
Lilly used nursing services as kickbacks to boost insulin prescriptions, lawsuit claimsAfter Novo Nordisk settled a lawsuit alleging it marketed certain drugs under a "white coat" sales scheme, fellow diabetes drug giant Eli Lilly is facing similar claims of illicit marketing. A recen2017/11/16
-
J&J's Xarelto pads artery disease case by reducing amputation, death rates vs. aspirinJohnson & Johnson is hoping Xarelto can win approval in peripheral and coronary artery disease patients after dropping positive data in August. Now, it has more results to back up its case—and hel2017/11/15
-
Ultragenyx snares FDA nod for ultraorphan med Mepsevii, and a valuable voucher, tooRare disease biotech Ultragenyx has won its firstFDA approvalwith Mepsevii, an enzyme replacement therapy expected to carry a high price to treat a tiny group of patients. And with that approval, Ul2017/11/15
-
With only 2 warnings in 2017, pharma's ad police hits historic lowAs the end of the year nears, the pharma industry can usually look back at FDA enforcement letters for insight into the agency'sthinking and guidance on marketing communications. But this year, there’2017/11/14
-
Merck, GlaxoSmithKline face hepatitis A vaccine shortage amid U.S. outbreaksIt was only August when Merck and GlaxoSmithKline had to deal with a global shortage of their hepatitis B vaccines, and now unexpected demand in the U.S. has sent both companies scrambling to cope wit2017/11/14
-
FDA eyes even more pricing competition with another round of generics movesCongress hasn't made any progress on drug pricing legislation, but that hasn't stopped the government from acting. Now, FDA Commissioner Scott Gottlieb has unveiled yet another move to step up compe2017/11/13
-
Takeda, Lundbeck plan U.S. test for depression app in latest beyond-the-pill forayCan keeping track of medication doses and mood swings help improve depression treatment? Takeda is tackling another beyond-the-pill tech project aimed at finding out. The pharma hasteamedwith Lundb2017/11/13